UCB agreed to acquire Candid Therapeutics for $2 billion upfront, positioning the deal as part of a broader push into next-generation autoimmune treatments. The transaction centers on Candid’s antibody portfolio and UCB’s intention to scale bispecific and T-cell engaging capabilities across immunological conditions. UCB’s strategy also includes a path to integrate Candid’s licensed antibody assets from China-based biotechs, which UCB characterizes as an emerging source of immunology innovation. The company’s approach signals that big pharma is prioritizing scalable platforms and late-preclinical/clinical assets rather than waiting for internal discovery cycles. The deal’s competitive angle is heightened by the framing that it would “join Gilead in autoimmune field” through an accelerated buildout of T-cell engager ambitions, a segment that remains one of the most capital-intensive and scrutinized areas in immunotherapy.